JP2015509535A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509535A5
JP2015509535A5 JP2014561024A JP2014561024A JP2015509535A5 JP 2015509535 A5 JP2015509535 A5 JP 2015509535A5 JP 2014561024 A JP2014561024 A JP 2014561024A JP 2014561024 A JP2014561024 A JP 2014561024A JP 2015509535 A5 JP2015509535 A5 JP 2015509535A5
Authority
JP
Japan
Prior art keywords
halo
cyano
optionally substituted
pharmaceutical composition
hydrocarbyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561024A
Other languages
English (en)
Japanese (ja)
Other versions
JP6418950B2 (ja
JP2015509535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029056 external-priority patent/WO2013134228A1/en
Publication of JP2015509535A publication Critical patent/JP2015509535A/ja
Publication of JP2015509535A5 publication Critical patent/JP2015509535A5/ja
Application granted granted Critical
Publication of JP6418950B2 publication Critical patent/JP6418950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561024A 2012-03-09 2013-03-05 ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法 Active JP6418950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
US61/608,765 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (3)

Publication Number Publication Date
JP2015509535A JP2015509535A (ja) 2015-03-30
JP2015509535A5 true JP2015509535A5 (OSRAM) 2016-04-21
JP6418950B2 JP6418950B2 (ja) 2018-11-07

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561024A Active JP6418950B2 (ja) 2012-03-09 2013-03-05 ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法

Country Status (25)

Country Link
US (3) US8946415B2 (OSRAM)
EP (1) EP2834243B1 (OSRAM)
JP (1) JP6418950B2 (OSRAM)
KR (1) KR101965025B1 (OSRAM)
CN (1) CN104302649B (OSRAM)
AR (1) AR090292A1 (OSRAM)
AU (1) AU2013230128B2 (OSRAM)
BR (1) BR112014022000A8 (OSRAM)
CA (1) CA2866143C (OSRAM)
DK (1) DK2834243T3 (OSRAM)
ES (1) ES2676224T3 (OSRAM)
HU (1) HUE038786T2 (OSRAM)
IL (1) IL234486A (OSRAM)
IN (1) IN2014DN07384A (OSRAM)
MX (2) MX345830B (OSRAM)
NZ (1) NZ630721A (OSRAM)
PL (1) PL2834243T3 (OSRAM)
PT (1) PT2834243T (OSRAM)
RU (1) RU2014140735A (OSRAM)
SG (1) SG11201405561RA (OSRAM)
TR (1) TR201808280T4 (OSRAM)
TW (1) TW201341386A (OSRAM)
UY (1) UY34668A (OSRAM)
WO (1) WO2013134228A1 (OSRAM)
ZA (1) ZA201406149B (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969565B2 (en) 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
HUE038786T2 (hu) 2012-03-09 2018-11-28 Lexicon Pharmaceuticals Inc Pirazolo[1,5-a]pirimidin-alapú vegyületek, ezeket tartalmazó kompozíciók és eljárások alkalmazásukra
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アダプター関連キナーゼ1(aak1)の阻害剤としての5h−クロメノ[3,4−c]ピリジン
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN110317214B (zh) 2014-01-24 2022-11-22 特普医药公司 作为蛋白质激酶的调节剂的二芳基巨环
US9932320B2 (en) * 2014-01-31 2018-04-03 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
EP3200797A1 (en) * 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
AU2015365587B2 (en) * 2014-12-15 2020-07-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as TRK inhibitors
ES2740224T3 (es) 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. ジアリール大環状多形
JP6817287B2 (ja) 2015-07-21 2021-01-20 ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. キラルジアリール大環状分子及びその使用
SG11201803605YA (en) 2015-11-02 2018-05-30 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
US10947242B2 (en) 2016-11-02 2021-03-16 Janssen Pharmaceutica, Nv [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors
CA3038916A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
WO2018083101A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7224334B2 (ja) 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
EP3724191B9 (en) * 2017-12-15 2022-05-18 Pyramid Biosciences, Inc. 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
JOP20200152A1 (ar) 2017-12-19 2022-10-30 Turning Point Therapeutics Inc مركبات حلقية كبرى لعلاج مرض
JP7150356B2 (ja) * 2017-12-22 2022-10-11 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ[1,5-a]ピリミジン化合物並びにその医薬組成物および使用
WO2019144885A1 (zh) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
EP3856743A4 (en) * 2018-09-27 2022-06-15 Fochon Pharmaceuticals, Ltd. SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2020081508A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2021216441A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections
EP4138844A1 (en) * 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
WO2025054448A1 (en) * 2023-09-08 2025-03-13 Satellos Bioscience Inc. Ap2 associated kinase 1 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
PT2725028T (pt) * 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8865726B2 (en) 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
US8946237B2 (en) * 2010-01-14 2015-02-03 Merck Sharp & Dohme Corp. Pyrazolo[1,5-A]pyrimidines as mark inhibitors
ES2671748T3 (es) * 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
US8969565B2 (en) 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
PL2822555T3 (pl) * 2012-03-09 2018-04-30 Lexicon Pharmaceuticals Inc Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu
HUE038786T2 (hu) 2012-03-09 2018-11-28 Lexicon Pharmaceuticals Inc Pirazolo[1,5-a]pirimidin-alapú vegyületek, ezeket tartalmazó kompozíciók és eljárások alkalmazásukra
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法

Similar Documents

Publication Publication Date Title
JP2015509535A5 (OSRAM)
JP2015509534A5 (OSRAM)
JP2016529319A5 (OSRAM)
JP2016529315A5 (OSRAM)
JP2016540742A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2015537020A5 (OSRAM)
JP2020502092A5 (OSRAM)
JP2017504635A5 (OSRAM)
JP2017514830A5 (OSRAM)
JP2016514159A5 (OSRAM)
JP2013542261A5 (OSRAM)
JP2018524390A5 (OSRAM)
JP2017519781A5 (OSRAM)
CY1118107T1 (el) Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr
JP2014506907A5 (OSRAM)
JP2015531773A5 (OSRAM)
JP2014511892A5 (OSRAM)
JP2014500861A5 (OSRAM)
JP2014037426A5 (OSRAM)
JP2014114295A5 (OSRAM)
JP2011529054A5 (OSRAM)
JP2016519165A5 (OSRAM)
JP2017505293A5 (OSRAM)
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk